GEHC Eyes icometrix Buyout to Strengthen Neurology Imaging Portfolio

GE HealthCare GEHC has recently announced plans to acquire Belgium-based icometrix, a company specializing in AI-powered brain imaging solutions, in a move designed to advance its precision care strategy and expand its neurological care portfolio. The deal underscores GE’s efforts to address the rising demand for MRI-driven insights in managing complex neurological conditions such as Alzheimer’s disease.

The deal is likely to strengthen the company’s position in the precision care, primarily in neurology. By integrating icometrix’s AI-powered insights with GEHC’s advanced imaging technologies, GEHC aims to empower care teams with the clarity and confidence needed to navigate complex neurological conditions.

The financial terms of the deal remain undisclosed. GE HealthCare intends to fund the acquisition with cash on hand, pending customary regulatory approvals.

Likely Trend of GEHC Stock Following the News

Shares of GE HealthCare have lost 0.6% so far this year against the industry’s gain of 6.6%. The S&P 500 Index has increased 12.7% in that period.

GE HealthCare’s move to acquire icometrix could be seen as a strategic long-term growth catalyst, reinforcing its positioning in the fast-expanding neurology and Alzheimer’s care markets. The deal highlights GE’s commitment to precision care and AI-driven imaging, areas expected to see rising demand. In the near term, the stock may experience muted movement given broader market conditions, but over time, the acquisition could strengthen recurring revenue streams and bolster GEHC’s competitive edge in neurological diagnostics.

More on the deal

At the core of icometrix’s offerings is its icobrain platform, which provides quantitative analysis of brain MRI scans across a spectrum of disorders, including multiple sclerosis, dementia, epilepsy, stroke and traumatic brain injury. Notably, icobrain aria stands out as the first FDA-cleared computer-aided detection and diagnosis solution for Amyloid Related Imaging Abnormalities (ARIA), a known side effect of amyloid-targeting therapies approved to treat Alzheimer’s disease. icometrix also collaborates with pharmaceutical companies to support drug development, clinical trials and real-world evidence generation

GE HealthCare plans to integrate icometrix’s solutions across its MRI platforms, streamlining workflows with its existing AI-driven technologies, including AIR x Brain, AIR Recon DL, and SONIC DL 3D. The company also intends to broaden access to icobrain aria across all vendor MRI systems, supporting radiologists and neurologists in efficiently handling growing scan volumes while maintaining high standards of care.

According to the Alzheimer’s Association, the number of adults living with Alzheimer’s is projected to double by 2050, fueled by global aging trends and broader adoption of anti-amyloid therapies. With such therapies requiring frequent neurological MRI exams to assess eligibility and monitor side effects, demand for advanced imaging and decision-support tools is expected to accelerate.

GE HealthCare Technologies Inc. Price

GE HealthCare Technologies Inc. price | GE HealthCare Technologies Inc. Quote

GEHC’s Zacks Rank & Other Key Picks

Currently, GEHC carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the broader medical space are West Pharmaceutical Services, Inc. WST, Medpace Holdings, Inc. MEDP and Boston Scientific BSX.

West Pharmaceutical reported second-quarter 2025 adjusted EPS of $1.84, which beat the Zacks Consensus Estimate by 21.9%. Revenues of $766.5 million surpassed the Zacks Consensus Estimate by 5.4%. It currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

West Pharmaceutical has a long-term estimated growth rate of 8.5%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.

Medpace Holdings, sporting a Zacks Rank of 1, reported second-quarter 2025 EPS of $3.10, which beat the Zacks Consensus Estimate by 3.3%. Revenues of $603.3 million outpaced the consensus mark by 11.5%.

Medpace Holdings has a long-term estimated growth rate of 11.4%. MEDP’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 13.9%.

Boston Scientific reported second-quarter 2025 adjusted EPS of 75 cents, which beat the Zacks Consensus Estimate by 4.2%. Revenues of $5.06 billion surpassed the Zacks Consensus Estimate by 3.5%. It currently carries a Zacks Rank #2.

Boston Scientific has a long-term estimated growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.11%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research